1. Home
  2. GNPX vs ERNA Comparison

GNPX vs ERNA Comparison

Compare GNPX & ERNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Genprex Inc.

GNPX

Genprex Inc.

N/A

Current Price

$1.68

Market Cap

2.2M

Sector

Health Care

ML Signal

N/A

Logo Eterna Therapeutics Inc.

ERNA

Eterna Therapeutics Inc.

N/A

Current Price

$1.59

Market Cap

2.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GNPX
ERNA
Founded
2009
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.2M
2.4M
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
GNPX
ERNA
Price
$1.68
$1.59
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
★ 110.6K
12.0K
Earning Date
11-13-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 31.29
EPS
N/A
★ N/A
Revenue
N/A
★ $582,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.42
$1.57
52 Week High
$9.99
$37.50

Technical Indicators

Market Signals
Indicator
GNPX
ERNA
Relative Strength Index (RSI) 31.86 28.97
Support Level $0.80 N/A
Resistance Level $2.42 $2.15
Average True Range (ATR) 0.19 0.18
MACD -0.01 0.01
Stochastic Oscillator 2.80 5.31

Price Performance

Historical Comparison
GNPX
ERNA

About GNPX Genprex Inc.

Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System, which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Gene Therapy (quaratusugene ozeplasmid), is initially being developed in combination with prominent, approved cancer drugs to treat Non-Small Cell Lung Cancer (NSCLC) and Small Cell Lung Cancer (SCLC).

About ERNA Eterna Therapeutics Inc.

Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.

Share on Social Networks: